Cancer Detection and Diagnosis Research in Massachusetts
Cancer Detection and Diagnosis Research (93.394) awarded $234 million to recipients in Massachusetts in 181 grants from fiscal 2021 to 2025, 8.7% of the program's national total. The General Hospital Corporation received the most, $80.0 million.
- Awarded in Massachusetts$234 million
- Awards181
- Share of the program8.7%
- Rank among states3rd of 45
- National total$2.7 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 99 | $47.0 million |
| FY 2022 | 94 | $48.7 million |
| FY 2023 | 91 | $45.2 million |
| FY 2024 | 82 | $38.9 million |
| FY 2025 | 84 | $53.7 million |
Recipients in Massachusetts
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Nonprofits | 53 | $80.0 million |
| Dana-Farber Cancer Institute, Inc. | Nonprofits | 24 | $33.4 million |
| Brigham & Womens Hospital Inc | Nonprofits | 14 | $18.7 million |
| The Broad Institute, Inc | Nonprofits | 8 | $12.9 million |
| Massachusetts Institute of Technology | Colleges and universities | 9 | $9.7 million |
| Beth Israel Deaconess Medical Center, Inc. | Nonprofits | 6 | $8.3 million |
| Trustees of Boston University | Colleges and universities | 5 | $6.1 million |
| Northeastern University | Colleges and universities | 5 | $5.6 million |
| Trustees of Tufts College | Colleges and universities | 4 | $5.1 million |
| Tufts Medical Center Parent, Inc. | Nonprofits | 2 | $4.4 million |
Open opportunities under this program
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
See all 50 on the program page
Questions people ask
How much Cancer Detection and Diagnosis Research money goes to Massachusetts?
$234 million from fiscal 2021 to 2025, across 181 awards. Massachusetts ranks 3rd of 45 states and territories for this program.
Who receives Cancer Detection and Diagnosis Research money in Massachusetts?
The largest recipient is The General Hospital Corporation, with $80.0 million in 53 awards. Next are Dana-Farber Cancer Institute, Inc. and Brigham & Womens Hospital Inc.
Can organizations in Massachusetts apply now?
Yes, 50 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Detection and Diagnosis Research in other states
Other large programs in Massachusetts
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- Children's Health Insurance Program
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- Temporary Assistance for Needy Families
- Federal Transit Formula Grants
- National School Lunch Program
- Allergy and Infectious Diseases Research
- Aging Research